Director Michael H. Mulroy reports acquisition of $26,100 in Lineage Cell Therapeutics common shares
LCTX•Lineage Cell Therapeutics director Michael H. Mulroy purchased 30,000 common shares at $0.87 each, increasing his directly owned holdings to 328,555 shares.




